Tissue resident macrophages: Key players in the pathogenesis of type 2 diabetes and its complications

Clinica Chimica Acta

Volumn 462, Issue , 2016, Pages 77-89

  Meshkani, Reza ^a   Vakili, Sanaz ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Atherosclerosis; Beta cell dysfunction; Chemokines; Cytokines; Diabetes; Inflammation; Insulin resistance; Macrophages; Nephropathy; Neuropathy; Retinopathy

Indexed keywords

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL MIGRATION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; HUMAN; INFLAMMATION; KUPFFER CELL; MACROPHAGE; MACROPHAGE FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; ANIMAL; COMPLICATION; LIVER; METABOLISM; PATHOLOGY;

ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INSULIN-SECRETING CELLS; LIVER; MACROPHAGES; MUSCLE, SKELETAL;

EID: 84986571261     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.08.015     Document Type: Review

References (166)

1. [1] Guariguata, L., Whiting, D.R., Hambleton, I., Beagley, J., Linnenkamp, U., Shaw, J.E., Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res. Clin. Pract. 103:2 (2014), 137–149.
2. [2] Meshkani, R., Adeli, K., Mechanisms linking the metabolic syndrome and cardiovascular disease: role of hepatic insulin resistance. J. Tehran Univ. Heart Cent. 4:2 (2009), 77–84.
3. [3] Kennedy, A., Martinez, K., Chuang, C.-C., LaPoint, K., McIntosh, M., Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: mechanisms of action and implications. J. Nutr. 139:1 (2009), 1–4.
4. [4] Olefsky, J.M., Glass, C.K., Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72 (2010), 219–246.
5. [5] Lee, J., Adipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance and type 2 diabetes. Arch. Pharm. Res. 36:2 (2013), 208–222.
6. [6] Abdulreda, M.H., Berggren, P.O., Islet inflammation in plain sight. Diabetes Obes. Metab. 15:s3 (2013), 105–116.
7. [7] Hickey, F.B., Martin, F., Diabetic kidney disease and immune modulation. Curr. Opin. Pharmacol. 13:4 (2013), 602–612.
8. [8] Silva, M.T., Neutrophils and macrophages work in concert as inducers and effectors of adaptive immunity against extracellular and intracellular microbial pathogens. J. Leukoc. Biol. 87:5 (2010), 805–813.
9. [9] Lee, B.-C., Lee, J., Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance. Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1842:3 (2014), 446–462.
10. [10] Gordon, S., Taylor, P.R., Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5:12 (2005), 953–964.
11. [11] Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., Tartaglia, L.A., Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Investig., 112(12), 2003, 1821.
12. [12] Davies, L.C., Jenkins, S.J., Allen, J.E., Taylor, P.R., Tissue-resident macrophages. Nat. Immunol. 14:10 (2013), 986–995.
13. [13] Nagareddy, P.R., Kraakman, M., Masters, S.L., Stirzaker, R.A., Gorman, D.J., Grant, R.W., Dragoljevic, D., Hong, E.S., Abdel-Latif, A., Smyth, S.S., Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab. 19:5 (2014), 821–835.
14. [14] Prerna, B., Chih-Hao, L., Role and function of macrophages in the metabolic syndrome. Biochem. J. 442:2 (2012), 253–262.
15. [15] Gordon, S., Plüddemann, A., Martinez Estrada, F., Macrophage heterogeneity in tissues: phenotypic diversity and functions. Immunol. Rev. 262:1 (2014), 36–55.
16. −. Chronic Systolic Heart Failure Patients, Mediat. Inflamm. 2012, 2012, 9.
17. [17] Ziegler-Heitbrock, L., The CD14 + CD16 + blood monocytes: their role in infection and inflammation. J. Leukoc. Biol. 81:3 (2007), 584–592.
18. [18] Schenk, S., Saberi, M., Olefsky, J.M., Insulin sensitivity: modulation by nutrients and inflammation. J. Clin. Invest. 118:9 (2008), 2992–3002.
19. [19] Weisberg, S.P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R.L., Ferrante, A.W. Jr., CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 116:1 (2006), 115–124.
20. [20] Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K.-i., Kitazawa, R., Kitazawa, S., Miyachi, H., Maeda, S., Egashira, K., MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Investig., 116(6), 2006, 1494.
21. [21] Kamei, N., Tobe, K., Suzuki, R., Ohsugi, M., Watanabe, T., Kubota, N., Ohtsuka-Kowatari, N., Kumagai, K., Sakamoto, K., Kobayashi, M., Overexpression of monocyte chemoattractant protein-1 in adipose tissues causes macrophage recruitment and insulin resistance. J. Biol. Chem. 281:36 (2006), 26602–26614.
22. [22] Inouye, K.E., Shi, H., Howard, J.K., Daly, C.H., Lord, G.M., Rollins, B.J., Flier, J.S., Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 56:9 (2007), 2242–2250.
23. [23] Kirk, E., Sagawa, Z., McDonald, T., O'Brien, K., Heinecke, J., Macrophage chemoattractant protein-1 deficiency fails to restrain macrophage infiltration into adipose tissue (vol 57, pg 1254, 2008). Diabetes, 57(9), 2008, 2552.
24. [24] Balasubramanyam, A., The role of the immune system in obesity and insulin resistance. J. Obes., 2013 (2013).
25. [25] Anderson, E.K., Gutierrez, D.A., Hasty, A.H., Adipose tissue recruitment of leukocytes. Curr. Opin. Lipidol., 21(3), 2010, 172.
26. [26] Cassetta, L., Cassol, E., Poli, G., Macrophage polarization in health and disease. Sci. World J. 11 (2011), 2391–2402.
27. [27] Biswas, S.K., Chittezhath, M., Shalova, I.N., Lim, J.-Y., Macrophage polarization and plasticity in health and disease. Immunol. Res. 53:1–3 (2012), 11–24.
28. [28] Gustafsson, C., Mjosberg, J., Matussek, A., Geffers, R., Matthiesen, L., Berg, G., Sharma, S., Buer, J., Ernerudh, J., Gene expression profiling of human decidual macrophages: evidence for immunosuppressive phenotype. PLoS One, 3(4), 2008, e2078.
29. [29] Zeyda, M., Stulnig, T.M., Adipose tissue macrophages. Immunol. Lett. 112:2 (2007), 61–67.
30. [30] Shoelson, S.E., Herrero, L., Naaz, A., Obesity, inflammation, and insulin resistance. Gastroenterology 132:6 (2007), 2169–2180.
31. [31] Sell, H., Habich, C., Eckel, J., Adaptive immunity in obesity and insulin resistance. Nat. Rev. Endocrinol. 8:12 (2012), 709–716.
32. [32] Bornstein, S.R., Abu-Asab, M., Glasow, A., Päth, G., Hauner, H., Tsokos, M., Chrousos, G.P., Scherbaum, W.A., Immunohistochemical and ultrastructural localization of leptin and leptin receptor in human white adipose tissue and differentiating human adipose cells in primary culture. Diabetes 49:4 (2000), 532–538.
33. [33] Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., Ferrante, A.W. Jr., Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Investig., 112(12), 2003, 1796.
34. [34] Solinas, G., Vilcu, C., Neels, J.G., Bandyopadhyay, G.K., Luo, J.-L., Naugler, W., Grivennikov, S., Wynshaw-Boris, A., Scadeng, M., Olefsky, J.M., JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab. 6:5 (2007), 386–397.
35. [35] Cinti, S., Mitchell, G., Barbatelli, G., Murano, I., Ceresi, E., Faloia, E., Wang, S., Fortier, M., Greenberg, A.S., Obin, M.S., Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 46:11 (2005), 2347–2355.
36. [36] Lumeng, C.N., DeYoung, S.M., Bodzin, J.L., Saltiel, A.R., Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 56:1 (2007), 16–23.
37. [37] Di Gregorio, G.B., Yao-Borengasser, A., Rasouli, N., Varma, V., Lu, T., Miles, L.M., Ranganathan, G., Peterson, C.A., McGehee, R.E., Kern, P.A., Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 54:8 (2005), 2305–2313.
38. [38] Jenkins, S.J., Ruckerl, D., Cook, P.C., Jones, L.H., Finkelman, F.D., van Rooijen, N., MacDonald, A.S., Allen, J.E., Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 332:6035 (2011), 1284–1288.
39. [39] Morinaga, H., Talukdar, S., Bae, E.J., Olefsky, J.M., Increased macrophage migration into adipose tissue in obese mice. Diabetes 61:2 (2012), 346–354.
40. [40] Hosogai, N., Fukuhara, A., Oshima, K., Miyata, Y., Tanaka, S., Segawa, K., Furukawa, S., Tochino, Y., Komuro, R., Matsuda, M., Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56:4 (2007), 901–911.
41. [41] Chen, A., Mumick, S., Zhang, C., Lamb, J., Dai, H., Weingarth, D., Mudgett, J., Chen, H., MacNeil, D.J., Reitman, M.L., Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes. Res. 13:8 (2005), 1311–1320.
42. [42] Tateya, S., Tamori, Y., Kawaguchi, T., Kanda, H., Kasuga, M., An increase in the circulating concentration of monocyte chemoattractant protein-1 elicits systemic insulin resistance irrespective of adipose tissue inflammation in mice. Endocrinology 151:3 (2010), 971–979.
43. [43] Gutierrez, D.A., Kennedy, A., Orr, J.S., Anderson, E.K., Webb, C.D., Gerrald, W.K., Hasty, A.H., Aberrant accumulation of undifferentiated myeloid cells in the adipose tissue of CCR2-deficient mice delays improvements in insulin sensitivity. Diabetes 60:11 (2011), 2820–2829.
44. [44] Surmi, B.K., Webb, C.D., Ristau, A.C., Hasty, A.H., Absence of macrophage inflammatory protein-1α does not impact macrophage accumulation in adipose tissue of diet-induced obese mice. Am. J. Physiol. Endocrinol. Metab. 299:3 (2010), E437–E445.
45. [45] Nara, N., Nakayama, Y., Okamoto, S., Tamura, H., Kiyono, M., Muraoka, M., Tanaka, K., Taya, C., Shitara, H., Ishii, R., Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance. J. Biol. Chem. 282:42 (2007), 30794–30803.
46. [46] Keophiphath, M., Rouault, C., Divoux, A., Clément, K., Lacasa, D., CCL5 promotes macrophage recruitment and survival in human adipose tissue. Arterioscler. Thromb. Vasc. Biol. 30:1 (2010), 39–45.
47. [47] Kitade, H., Sawamoto, K., Nagashimada, M., Inoue, H., Yamamoto, Y., Sai, Y., Takamura, T., Yamamoto, H., Miyamoto, K.-i., Ginsberg, H.N., CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes 61:7 (2012), 1680–1690.
48. [48] Spite, M., Hellmann, J., Tang, Y., Mathis, S.P., Kosuri, M., Bhatnagar, A., Jala, V.R., Haribabu, B., Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity. J. Immunol. 187:4 (2011), 1942–1949.
49. [49] Kosteli, A., Sugaru, E., Haemmerle, G., Martin, J.F., Lei, J., Zechner, R., Ferrante, A.W. Jr., Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. J. Clin. Invest., 120(10), 2010, 3466.
50. [50] Laine, P.S., Schwartz, E.A., Wang, Y., Zhang, W.-Y., Karnik, S.K., Musi, N., Reaven, P.D., Palmitic acid induces IP-10 expression in human macrophages via NF-κB activation. Biochem. Biophys. Res. Commun. 358:1 (2007), 150–155.
51. [51] Nguyen, M.A., Favelyukis, S., Nguyen, A.-K., Reichart, D., Scott, P.A., Jenn, A., Liu-Bryan, R., Glass, C.K., Neels, J.G., Olefsky, J.M., A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 282:48 (2007), 35279–35292.
52. [52] Lee, J.Y., Ye, J., Gao, Z., Youn, H.S., Lee, W.H., Zhao, L., Sizemore, N., Hwang, D.H., Reciprocal modulation of Toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids. J. Biol. Chem. 278:39 (2003), 37041–37051.
53. [53] Shi, H., Kokoeva, M.V., Inouye, K., Tzameli, I., Yin, H., Flier, J.S., TLR4 links innate immunity and fatty acid–induced insulin resistance. J. Clin. Investig., 116(11), 2006, 3015.
54. [54] Shaul, M.E., Bennett, G., Strissel, K.J., Greenberg, A.S., Obin, M.S., Dynamic, M2-like remodeling phenotypes of CD11c + adipose tissue macrophages during high-fat diet–induced obesity in mice. Diabetes 59:5 (2010), 1171–1181.
55. [55] Kalupahana, N.S., Moustaid-Moussa, N., Claycombe, K.J., Immunity as a link between obesity and insulin resistance. Mol. Asp. Med. 33:1 (2012), 26–34.
56. [56] Li, P., Lu, M., Nguyen, M.A., Bae, E.J., Chapman, J., Feng, D., Hawkins, M., Pessin, J.E., Sears, D.D., Nguyen, A.-K., Functional heterogeneity of CD11c-positive adipose tissue macrophages in diet-induced obese mice. J. Biol. Chem. 285:20 (2010), 15333–15345.
57. [57] Fujisaka, S., Usui, I., Bukhari, A., Ikutani, M., Oya, T., Kanatani, Y., Tsuneyama, K., Nagai, Y., Takatsu, K., Urakaze, M., Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. Diabetes 58:11 (2009), 2574–2582.
58. [58] Huang, J.T., Welch, J.S., Ricote, M., Binder, C.J., Willson, T.M., Kelly, C., Witztum, J.L., Funk, C.D., Conrad, D., Glass, C.K., Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature 400:6742 (1999), 378–382.
59. [59] Odegaard, J.I., Ricardo-Gonzalez, R.R., Eagle, A.R., Vats, D., Morel, C.R., Goforth, M.H., Subramanian, V., Mukundan, L., Ferrante, A.W., Chawla, A., Alternative M2 activation of Kupffer cells by PPARδ ameliorates obesity-induced insulin resistance. Cell Metab. 7:6 (2008), 496–507.
60. [60] Meshkani, R., Adeli, K., Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin. Biochem. 42:13 (2009), 1331–1346.
61. [61] Li, Z., Diehl, A., Innate immunity in the liver. Curr. Opin. Gastroenterol. 19:6 (2003), 565–571.
62. [62] Farrell, G.C., Van Rooyen, D., Gan, L., Chitturi, S., NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications. Gut Liver, 6(2), 2012, 149.
63. [63] McArdle, M.A., Finucane, O.M., Connaughton, R.M., McMorrow, A.M., Roche, H.M., Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front. Endocrinol., 4, 2013.
64. [64] Bilzer, M., Roggel, F., Gerbes, A.L., Role of kupffer cells in host defense and liver disease. Liver Int. 26:10 (2006), 1175–1186.
65. [65] Szabo, G., Mandrekar, P., Dolganiuc, A., Innate immune response and hepatic inflammation. Semin. Liver Dis., 2007, 339–350.
66. [66] Su, G.L., Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am. J. Physiol. Gastrointest. Liver Physiol. 283:2 (2002), G256–G265.
67. [67] Adachi, Y., Bradford, B.U., Gao, W., Bojes, H.K., Thurman, R.G., Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 20:2 (1994), 453–460.
68. [68] Lumeng, C.N., Innate immune activation in obesity. Mol. Asp. Med. 34:1 (2013), 12–29.
69. [69] Obstfeld, A.E., Sugaru, E., Thearle, M., Francisco, A.-M., Gayet, C., Ginsberg, H.N., Ables, E.V., Ferrante, A.W., CC chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes 59:4 (2010), 916–925.
70. [70] Baffy, G., Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J. Hepatol. 51:1 (2009), 212–223.
71. [71] Hotamisligil, G.S., Shargill, N.S., Spiegelman, B.M., Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:5091 (1993), 87–91.
72. [72] Lesmana, C.R.A., Hasan, I., Budihusodo, U., Gani, R.A., Krisnuhoni, E., Akbar, N., Lesmana, L.A., Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis. J. Dig. Dis. 10:3 (2009), 201–206.
73. [73] Li, Z., Yang, S., Lin, H., Huang, J., Watkins, P.A., Moser, A.B., DeSimone, C., Song, X.-y., Diehl, A.M., Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37:2 (2003), 343–350.
74. [74] Knittel, T., Mehde, M., Kobold, D., Saile, B., Dinter, C., Ramadori, G., Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-α and TGF-β1. J. Hepatol. 30:1 (1999), 48–60.
75. [75] Cani, P.D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., Geurts, L., Naslain, D., Neyrinck, A., Lambert, D.M., Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58:8 (2009), 1091–1103.
76. [76] Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Masciana, R., Forgione, A., Gabrieli, M.L., Perotti, G., Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49:6 (2009), 1877–1887.
77. [77] Meli, R., Raso, G.M., Calignano, A., Role of innate immune response in non-alcoholic fatty liver disease: metabolic complications and therapeutic tools. Front. Immunol., 5, 2014.
78. [78] Bieghs, V., Trautwein, C., The innate immune response during liver inflammation and metabolic disease. Trends Immunol. 34:9 (2013), 446–452.
79. [79] Zhan, Y.-T., An, W., Roles of liver innate immune cells in nonalcoholic fatty liver disease. World J. Gastroenterol., 16(37), 2010, 4652.
80. [80] Cusi, K., Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 142:4 (2012), 711–725, e6.
81. [81] Alkhouri, N., Dixon, L.J., Feldstein, A.E., Lipotoxicity in Nonalcoholic Fatty Liver Disease: Not all Lipids Are Created Equal. 2009.
82. [82] Parvaneh, L., Meshkani, R., Bakhtiyari, S., MohammadTaghvaie, N., GorganiFiruzjaee, S., TaheriPak, G., Golestani, A., Foruzandeh, M., Larijani, B., Taghikhani, M., Palmitate and inflammatory state additively induce the expression of PTP1B in muscle cells. Biochem. Biophys. Res. Commun. 396:2 (2010), 467–471.
83. [83] Bakhtiyari, S., Meshkani, R., Taghikhani, M., Larijani, B., Adeli, K., Protein tyrosine phosphatase-1B (PTP-1B) knockdown improves palmitate-induced insulin resistance in C2C12 skeletal muscle cells. Lipids 45:3 (2010), 237–244.
84. [84] Kewalramani, G., Bilan, P.J., Klip, A., Muscle insulin resistance: assault by lipids, cytokines and local macrophages. Curr. Opin. Clin. Nutr. Metab. Care 13:4 (2010), 382–390.
85. [85] Bilan, P.J., Samokhvalov, V., Koshkina, A., Schertzer, J.D., Samaan, M.C., Klip, A., Direct and macrophage-mediated actions of fatty acids causing insulin resistance in muscle cells. Arch. Physiol. Biochem. 115:4 (2009), 176–190.
86. [86] Varma, V., Yao-Borengasser, A., Rasouli, N., Nolen, G.T., Phanavanh, B., Starks, T., Gurley, C., Simpson, P., McGehee, R.E., Kern, P.A., Muscle inflammatory response and insulin resistance: synergistic interaction between macrophages and fatty acids leads to impaired insulin action. Am. J. Physiol. Endocrinol. Metab. 296:6 (2009), E1300–E1310.
87. [87] Honda, H., Kimura, H., Rostami, A., Demonstration and phenotypic characterization of resident macrophages in rat skeletal muscle. Immunology, 70(2), 1990, 272.
88. [88] Hong, E.-G., Ko, H.J., Cho, Y.-R., Kim, H.-J., Ma, Z., Tim, Y.Y., Friedline, R.H., Kurt-Jones, E., Finberg, R., Fischer, M.A., Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. Diabetes 58:11 (2009), 2525–2535.
89. [89] Fink, L., Oberbach, A., Costford, S., Chan, K., Sams, A., Blüher, M., Klip, A., Expression of anti-inflammatory macrophage genes within skeletal muscle correlates with insulin sensitivity in human obesity and type 2 diabetes. Diabetologia 56:7 (2013), 1623–1628.
90. [90] Fink, L., Oberbach, A., Jensen, T., Sams, A., Blüher, M., Klip, A., Muscle-infiltrating macrophages in type 2 diabetes. Diabetes, 61, 2012, 106.
91. [91] Patsouris, D., Li, P.-P., Thapar, D., Chapman, J., Olefsky, J.M., Neels, J.G., Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 8:4 (2008), 301–309.
92. [92] Kim, J.K., Gimeno, R.E., Higashimori, T., Kim, H.-J., Choi, H., Punreddy, S., Mozell, R.L., Tan, G., Stricker-Krongrad, A., Hirsch, D.J., Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle. J. Clin. Investig., 113(5), 2004, 756.
93. [93] Samokhvalov, V., Bilan, P.J., Schertzer, J.D., Antonescu, C.N., Klip, A., Palmitate-and lipopolysaccharide-activated macrophages evoke contrasting insulin responses in muscle cells. Am. J. Physiol. Endocrinol. Metab. 296:1 (2009), E37–E46.
94. [94] MohammadTaghvaei, N., Meshkani, R., Taghikhani, M., Larijani, B., Adeli, K., Palmitate enhances protein tyrosine phosphatase 1B (PTP1B) gene expression at transcriptional level in C2C12 skeletal muscle cells. Inflammation 34:1 (2011), 43–48.
95. [95] MohammadTaghvaei, N., Taheripak, G., Taghikhani, M., Meshkani, R., Palmitate-induced PTP1B expression is mediated by ceramide-JNK and nuclear factor κB (NF-κB) activation. Cell. Signal. 24:10 (2012), 1964–1970.
96. [96] Coll, T., Palomer, X., Blanco-Vaca, F., Sánchez, R.M., Laguna, J.C., Vázquez-Carrera, M., Cyclooxygenase 2 inhibition exacerbates palmitate-induced inflammation and insulin resistance in skeletal muscle cells. Endocrinology, 2013.
97. [97] Green, C., Macrae, K., Fogarty, S., Hardie, D., Sakamoto, K., Hundal, H., Counter-modulation of fatty acid-induced pro-inflammatory nuclear factor kappaB signalling in rat skeletal muscle cells by AMP-activated protein kinase. Biochem. J. 435 (2011), 463–474.
98. [98] Jové, M., Planavila, A., Laguna, J.C., Vázquez-Carrera, M., Palmitate-induced interleukin 6 production is mediated by protein kinase C and nuclear-factor κB activation and leads to glucose transporter 4 down-regulation in skeletal muscle cells. Endocrinology 146:7 (2005), 3087–3095.
99. [99] Pillon, N.J., Arane, K., Bilan, P.J., Chiu, T.T., Klip, A., Muscle cells challenged with saturated fatty acids mount an autonomous inflammatory response that activates macrophages. Cell Commun. Signal, 10(1), 2012, 30.
100. [100] Potter, K.J., Westwell-Roper, C.Y., Klimek-Abercrombie, A.M., Warnock, G.L., Verchere, C.B., Death and dysfunction of transplanted β-cells: lessons learned from type 2 diabetes?. Diabetes 63:1 (2014), 12–19.
101. [101] Donath, M.Y., Dalmas, É., Sauter, N.S., Böni-Schnetzler, M., Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab. 17:6 (2013), 860–872.
102. [102] Boni-Schnetzler, M., Boller, S., Debray, S., Bouzakri, K., Meier, D.T., Prazak, R., Kerr-Conte, J., Pattou, F., Ehses, J.A., Schuit, F.C., Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 150:12 (2009), 5218–5229.
103. [103] Ehses, J.A., Perren, A., Eppler, E., Ribaux, P., Pospisilik, J.A., Maor-Cahn, R., Gueripel, X., Ellingsgaard, H., Schneider, M.K., Biollaz, G., Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56:9 (2007), 2356–2370.
104. [104] Rhodes, C.J., Type 2 diabetes-a matter of β-cell life and death?. Science 307:5708 (2005), 380–384.
105. [105] Boni-Schnetzler, M., Thorne, J., Parnaud, G., Marselli, L., Ehses, J.A., Kerr-Conte, J., Pattou, F., Halban, P.A., Weir, G.C., Donath, M.Y., Increased interleukin (IL)-1β messenger ribonucleic acid expression in β-cells of individuals with type 2 diabetes and regulation of IL-1β in human islets by glucose and autostimulation. J. Clin. Endocrinol. Metab. 93:10 (2008), 4065–4074.
106. [106] Eguchi, K., Manabe, I., Macrophages and islet inflammation in type 2 diabetes. Diabetes Obes. Metab. 15:s3 (2013), 152–158.
107. [107] Eguchi, K., Manabe, I., Oishi-Tanaka, Y., Ohsugi, M., Kono, N., Ogata, F., Yagi, N., Ohto, U., Kimoto, M., Miyake, K., Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation. Cell Metab. 15:4 (2012), 518–533.
108. [108] Masters, S.L., Dunne, A., Subramanian, S.L., Hull, R.L., Tannahill, G.M., Sharp, F.A., Becker, C., Franchi, L., Yoshihara, E., Chen, Z., Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 [beta] in type 2 diabetes. Nat. Immunol. 11:10 (2010), 897–904.
109. [109] Donath, M.Y., Böni-Schnetzler, M., Ellingsgaard, H., Ehses, J.A., Islet inflammation impairs the pancreatic β-cell in type 2 diabetes. Physiology 24:6 (2009), 325–331.
110. [110] Sun, Y.-M., Su, Y., Li, J., Wang, L.-F., Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem. Biophys. Res. Commun. 433:4 (2013), 359–361.
111. [111] Lim, A.K., Tesch, G.H., Inflammation in diabetic nephropathy. Mediat. Inflamm., 2012 (2012).
112. [112] Sassy-Prigent, C., Heudes, D., Mandet, C., Bélair, M.-F., Michel, O., Perdereau, B., Bariéty, J., Bruneval, P., Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 49:3 (2000), 466–475.
113. [113] Chow, F., Ozols, E., Nikolic-Paterson, D.J., Atkins, R.C., Tesch, G.H., Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 65:1 (2004), 116–128.
114. [114] Furuta, T., Saito, T., Ootaka, T., Soma, J., Obara, K., Abe, K., Yoshinaga, K., The role of macrophages in diabetic glomerulosclerosis. Am. J. Kidney Dis. 21:5 (1993), 480–485.
115. [115] Nguyen, D., Ping, F., Mu, W., Hill, P., Atkins, R.C., Chadban, S.J., Macrophage accumulation in human progressive diabetic nephropathy. Nephrology 11:3 (2006), 226–231.
116. [116] Morii, T., Fujita, H., Narita, T., Shimotomai, T., Fujishima, H., Yoshioka, N., Imai, H., Kakei, M., Ito, S., Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J. Diabetes Complicat. 17:1 (2003), 11–15.
117. [117] Kanamori, H., Matsubara, T., Mima, A., Sumi, E., Nagai, K., Takahashi, T., Abe, H., Iehara, N., Fukatsu, A., Okamoto, H., Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem. Biophys. Res. Commun. 360:4 (2007), 772–777.
118. [118] Chow, F., Nikolic-Paterson, D., Ma, F., Ozols, E., Rollins, B., Tesch, G., Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 50:2 (2007), 471–480.
119. [119] Chow, F.Y., Nikolic-Paterson, D.J., Ozols, E., Atkins, R.C., Tesch, G.H., Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J. Am. Soc. Nephrol. 16:6 (2005), 1711–1722.
120. [120] Galkina, E., Ley, K., Leukocyte recruitment and vascular injury in diabetic nephropathy. J. Am. Soc. Nephrol. 17:2 (2006), 368–377.
121. [121] Dalla Vestra, M., Mussap, M., Gallina, P., Bruseghin, M., Cernigoi, A.M., Saller, A., Plebani, M., Fioretto, P., Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J. Am. Soc. Nephrol. 16:3 Suppl. 1 (2005), S78–S82.
122. [122] McCarthy, E.T., Sharma, R., Sharma, M., Li, J.-Z., Ge, X.-L., Dileepan, K.N., Savin, V.J., TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J. Am. Soc. Nephrol. 9:3 (1998), 433–438.
123. [123] Urbančič, M., Kloboves Prevodnik, V., Petrovič, D., Globočnik Petrovič, M., A Flow Cytometric Analysis of Vitreous Inflammatory Cells in Patients with Proliferative Diabetic Retinopathy, BioMed Research International 2013. 2013.
124. [124] Forbes, J.M., Cooper, M.E., Mechanisms of diabetic complications. Physiol. Rev. 93:1 (2013), 137–188.
125. [125] Tang, J., Kern, T.S., Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 30:5 (2011), 343–358.
126. [126] Powell, E.U., Field, R., Diabetic retinopathy and rheumatoid arthritis. Lancet 284:7349 (1964), 17–18.
127. [127] Demircan, N., Safran, B., Soylu, M., Ozcan, A., Sizmaz, S., Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye 20:12 (2006), 1366–1369.
128. [128] Kowluru, R.A., Odenbach, S., Role of interleukin-1β in the development of retinopathy in rats: effect of antioxidants. Invest. Ophthalmol. Vis. Sci. 45:11 (2004), 4161–4166.
129. [129] Mocan, M.C., Kadayifcilar, S., Eldem, B., Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy. Can. J. Ophthalmol. 41:6 (2006), 747–752.
130. [130] Murugeswari, P., Shukla, D., Rajendran, A., Kim, R., Namperumalsamy, P., Muthukkaruppan, V., Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and Eales' disease. Retina 28:6 (2008), 817–824.
131. [131] Maier, R., Weger, M., Haller-Schober, E.-M., El-Shabrawi, Y., Wedrich, A., Theisl, A., Aigner, R., Barth, A., Haas, A., Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol. Vis., 14, 2008, 637.
132. [132] Adamiec-Mroczek, J., Oficjalska-Młyńczak, J., Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes—role of the inflammatory–immune process in the pathogenesis of proliferative diabetic retinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 246:12 (2008), 1665–1670.
133. [133] Hernandez, C., Segura, R., Fonollosa, A., Carrasco, E., Francisco, G., Simo, R., Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet. Med. 22:6 (2005), 719–722.
134. [134] Doganay, S., Evereklioglu, C., Er, H., Türköz, Y., Sevinc, A., Mehmet, N., Şavli, H., Comparison of serum NO, TNF-α, IL-1β, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 16:2 (2002), 163–170.
135. [135] Schröder, S., Palinski, W., Schmid-Schönbein, G., Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am. J. Pathol., 139(1), 1991, 81.
136. [136] Miyamoto, K., Khosrof, S., Bursell, S.-E., Rohan, R., Murata, T., Clermont, A.C., Aiello, L.P., Ogura, Y., Adamis, A.P., Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc. Natl. Acad. Sci. 96:19 (1999), 10836–10841.
137. [137] Esser, P., Heimann, K., Wiedemann, P., Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations. Br. J. Ophthalmol. 77:11 (1993), 731–733.
138. [138] Ishida, S., Usui, T., Yamashiro, K., Kaji, Y., Amano, S., Ogura, Y., Hida, T., Oguchi, Y., Ambati, J., Miller, J.W., VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J. Exp. Med. 198:3 (2003), 483–489.
139. [139] Tashimo, A., Mitamura, Y., Nagai, S., Nakamura, Y., Ohtsuka, K., Mizue, Y., Nishihira, J., Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy. Diabet. Med. 21:12 (2004), 1292–1297.
140. [140] F. Semeraro, Diabetic retinopathy: vascular and inflammatory disease.
141. [141] Zhang, W., Liu, H., Rojas, M., Caldwell, R.W., Caldwell, R.B., Anti-inflammatory therapy for diabetic retinopathy. Immunotherapy 3:5 (2011), 609–628.
142. [142] Tarr, J.M., Kaul, K., Chopra, M., Kohner, E.M., Chibber, R., Pathophysiology of Diabetic Retinopathy, ISRN Ophthalmology 2013. 2013.
143. [143] Sfikakis, P.P., Grigoropoulos, V., Emfietzoglou, I., Theodossiadis, G., Tentolouris, N., Delicha, E., Katsiari, C., Alexiadou, K., Hatziagelaki, E., Theodossiadis, P.G., Infliximab for diabetic macular edema refractory to laser photocoagulation a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care 33:7 (2010), 1523–1528.
144. [144] Edwards, J.L., Vincent, A.M., Cheng, H.T., Feldman, E.L., Diabetic neuropathy: mechanisms to management. Pharmacol. Ther. 120:1 (2008), 1–34.
145. [145] Farmer, K.L., Li, C., Dobrowsky, R.T., Diabetic peripheral neuropathy: should a chaperone accompany our therapeutic approach?. Pharmacol. Rev. 64:4 (2012), 880–900.
146. [146] Yasuda, H., Terada, M., Maeda, K., Kogawa, S., Sanada, M., Haneda, M., Kashiwagi, A., Kikkawa, R., Diabetic neuropathy and nerve regeneration. Prog. Neurobiol. 69:4 (2003), 229–285.
147. [147] Purwata, T.E., High TNF-alpha plasma levels and macrophages iNOS and TNF-alpha expression as risk factors for painful diabetic neuropathy. J. Pain Res., 4, 2011, 169.
148. [148] Yamakawa, I., Kojima, H., Terashima, T., Katagi, M., Oi, J., Urabe, H., Sanada, M., Kawai, H., Chan, L., Yasuda, H., Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am. J. Physiol. Endocrinol. Metab. 301:5 (2011), E844–E852.
149. [149] King, R., The role of glycation in the pathogenesis of diabetic polyneuropathy. Mol. Pathol., 54(6), 2001, 400.
150. [150] Sandireddy, R., Yerra, V.G., Areti, A., Komirishetty, P., Kumar, A., Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on these targets. Int. J. Endocrinol., 2014 (2014).
151. [151] Wang, Y., Schmeichel, A.M., Iida, H., Schmelzer, J.D., Low, P.A., Enhanced inflammatory response via activation of NF-κB in acute experimental diabetic neuropathy subjected to ischemia–reperfusion injury. J. Neurol. Sci. 247:1 (2006), 47–52.
152. [152] Conti, G., Scarpini, E., Baron, P., Livraghi, S., Tiriticco, M., Bianchi, R., Vedeler, C., Scarlato, G., Macrophage infiltration and death in the nerve during the early phases of experimental diabetic neuropathy: a process concomitant with endoneurial induction of IL-1β and p75NTR. J. Neurol. Sci. 195:1 (2002), 35–40.
153. [153] Kawamura, N., Dyck, P.J.B., Schmeichel, A.M., Engelstad, J.K., Low, P.A., Dyck, P.J., Inflammatory mediators in diabetic and non-diabetic lumbosacral radiculoplexus neuropathy. Acta Neuropathol. 115:2 (2008), 231–239.
154. [154] Xu, J.-M., Shi, G.-P., Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr. Rev. 33:1 (2012), 71–108.
155. [155] Viola, J., Soehnlein, O., Atherosclerosis–A Matter of Unresolved Inflammation, Seminars in Immunology. 2015, Elsevier.
156. [156] Colin, S., Chinetti-Gbaguidi, G., Staels, B., Macrophage phenotypes in atherosclerosis. Immunol. Rev. 262:1 (2014), 153–166.
157. [157] Witztum, J.L., Steinberg, D., The oxidative modification hypothesis of atherosclerosis: does it hold for humans?. Trends Cardiovasc. Med. 11:3 (2001), 93–102.
158. [158] Salvayre, R., Auge, N., Benoist, H., Negre-Salvayre, A., Oxidized low-density lipoprotein-induced apoptosis. Biochim. Biophys. Acta (BBA) - Mol. Biol. Lipids 1585:2 (2002), 213–221.
159. [159] Buckley, M.L., Ramji, D.P., The influence of dysfunctional signaling and lipid homeostasis in mediating the inflammatory responses during atherosclerosis. Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1852:7 (2015), 1498–1510.
160. [160] Soehnlein, O., Drechsler, M., Döring, Y., Lievens, D., Hartwig, H., Kemmerich, K., Ortega-Gómez, A., Mandl, M., Vijayan, S., Projahn, D., Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes. EMBO Mol. Med. 5:3 (2013), 471–481.
161. [161] Stoneman, V., Braganza, D., Figg, N., Mercer, J., Lang, R., Goddard, M., Bennett, M., Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ. Res. 100:6 (2007), 884–893.
162. [162] Potteaux, S., Gautier, E.L., Hutchison, S.B., van Rooijen, N., Rader, D.J., Thomas, M.J., Sorci-Thomas, M.G., Randolph, G.J., Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe −/− mice during disease regression. J. Clin. Invest., 121(5), 2011, 2025.
163. [163] Robbins, C.S., Hilgendorf, I., Weber, G.F., Theurl, I., Iwamoto, Y., Figueiredo, J.-L., Gorbatov, R., Sukhova, G.K., Gerhardt, L.M., Smyth, D., Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat. Med. 19:9 (2013), 1166–1172.
164. [164] Chistiakov, D.A., Bobryshev, Y.V., Nikiforov, N.G., Elizova, N.V., Sobenin, I.A., Orekhov, A.N., Macrophage phenotypic plasticity in atherosclerosis: the associated features and the peculiarities of the expression of inflammatory genes. Int. J. Cardiol. 184 (2015), 436–445.
165. [165] Leitinger, N., Schulman, I.G., Phenotypic polarization of macrophages in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 33:6 (2013), 1120–1126.
166. [166] Wolfs, I.M., Donners, M., de Winther, M.P., Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb. Haemost., 106(5), 2011, 763.